Oncology

#Cancer research #Drug discovery #European Society for Medical Oncology #Oncology

This week in drug discovery (5-9 September)

News round-up for 5-9 September by DDW Digital Content Editor Diana Spencer Cancer research has been making headlines over the last seven days in the build-up to the European Society for Medical Oncology (ESMO) Congress 2022. Notably, it was a mixed week for PARP inhibitor olaparib, which was approved by regulator… Read More

#News

#Biomarkers #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research

NICE rejects prostate cancer drug due to cost of genetic testing

The National Institute of Health and Care Excellence (NICE) has confirmed its decision not to recommend olaparib for previously treated metastatic prostate cancer in patients with BRCA gene mutations. The Institute of Cancer Research (ICR) has called the decision ‘disappointing’ and ‘frustrating’. It means that men in England and Wales… Read More

#Cancer Research #News #Trending News

ESMO Congress, Paris
#Cancer research #Immuno-oncology #Oncology

GSK to share oncology findings at ESMO

GSK will present its latest gynaecological cancer research at the European Society for Medical Oncology (ESMO) Congress 2022 (September 9-13). The company will share positive trial data on its gynaecological cancer treatments Zejula (niraparib) and Jemperli (dostarlimab), as well as early-stage research in immuno-oncology and real-world evidence assessing treatment patterns… Read More

#Cancer Research #News

#AI #Drug discovery #Machine learning #Oncology

The role of machine learning in cancer drug development

Throughout the continuum of drug development, from target discovery to patient selection, machine learning approaches are being adopted to reliably mine vast amounts of data and make predictions with higher accuracy Anita Ramanathan discusses how machine learning is currently used across different stages of cancer research.  Applying computational methods to… Read More

#Cancer Research #Exclusive Content

#Breast cancer #Drug discovery #Oncology

Nitric oxide could form treatment approach for breast cancer

A new therapeutic approach for triple negative breast cancer using nitric oxide is being explored by researchers at the medical research centre CÚRAM. Amir Abdo Alsharabasy, a CÚRAM doctoral candidate working in the laboratory of Professor Abhay Pandit, is working on the design of nitric oxide scavengers to form a… Read More

#News

#Cancer research #Immunotherapy #Oncology #T-Cells

Blocking key enzyme boosts anti-cancer T-cell responses

A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumour-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in… Read More

#Cancer Research #Editor's Choice #News

EMA concept
#Clinical trials #EMA #Oncology #Regulatory

Combination treatment for AML closer to approval following EMA nod

The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy.  The MMA was granted to Otsuka Pharmaceutical and Astex Pharmaceuticals’ oral fixed-dose combination of decitabine and cedazuridine (ASTX727).   The… Read More

#Cancer Research #News #Regulatory

#Appointment #Covid-19 #EMA #MHRA #Oncology

This week in drug discovery (15-19 August)

News round-up by DDW Editor Reece Armstrong for 15-19 August. Covid booster approvals, positive results for Malaria vaccines and new CEOs are some of the stories in this week’s news round-up.  MHRA approves Moderna’s bivalent Covid booster   The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated… Read More

#News

#Biology #Clinical trials #Diversity #Oncology

What it takes to make cancer research more inclusive

The drug discovery sector is working to address cancer disparities. Anita Ramanathan examines the importance of inclusivity and diversity throughout the drug discovery and development process.  While the risk of cancer is universal, some groups are disproportionately affected by cancer compared to others. Disparities resulting from genetic, environmental, social, and… Read More

#Cancer Research #Exclusive Content

#AstraZeneca #Breast cancer #Institute of Cancer Research #Oncology

EMA approves early-stage breast cancer treatment  

A precision medicine for early-stage breast cancer has been approved by the European Medicines Agency (EMA).   Developed by AstraZeneca and Merck & Co (MSD) under the brand name Lynparza, the treatment is a precision medicine which blocks DNA damage response (DDR) in cells or tumours that have… Read More

#Cancer Research #News

#Alzheimer's #Business #Immunology / Virology & Vaccines #Oncology

This week in drug discovery (8-12 August)  

News round-up by DDW’s Reece Armstrong for 8-12 August  New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine    Pfizer… Read More

#News

#London #Oncology #The Institute of Cancer Research

Scientists discover how melanoma invades new tissue  

Scientists have discovered how melanoma skin cancer cells invade new tissues in research they hope might lead to new treatments.  A team from The Institute of Cancer Research, London discovered that melanoma cells harness a gene usually used by growing nerves to escape from their immediate area… Read More

#Cancer Research #News

#Diagnostics #Neurology #Oncology

Research paves way for easier brain tumour diagnosis  

New research could pave the way to the earlier diagnosis of brain tumours through the development of a simple blood test for glioblastomas.  Researchers from the University of Bristol in the UK, developed mathematical models to assess the current use of biomarkers in the detection of glioblastomas… Read More

#News

Colorectal cancer
#Clinical trial #Immunotherapy #Oncology

Excitement at rectal cancer immunotherapy breakthrough

Listen to this article on the DDW Podcast: A ground breaking ‘immunoablative’ neoadjuvant immunotherapy clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has reported a 100% complete response rate in MMRd locally advanced rectal cancer. Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New… Read More

#Exclusive Content

#Cancer #Genetics #Oncology

Could elephant genes hold the key to avoiding cancers?

Scientists modelling the cancer-suppressing p53 gene identify how the 20 different molecules unique to elephants get activated for increased sensitivity and response against carcinogenic conditions – with implications for cancer treatments in humans. Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used… Read More

#Cancer Research #Editor's Choice #News